Ascendia

  MARKET NEWS

Santhera Launches Vamorolone in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
Henlius & Sermonix Announce Strategic Collaboration & Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic ALS
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

  FEATURED EDITORIAL

  COMPANY PROFILE

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through the Celanese Development & Feasibility Lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Contract Packaging Predicted to See High Growth in 2024 Ahead of Pharmapack Europe

Contract Packaging Predicted to See High Growth in 2024 Ahead of Pharmapack Europe

The outlook for pharma services in 2024 is continuing to improve, with 94% of the industry either “moderately positive” (37%) or “highly positive” (37%) on growth for contract packaging in….

STADA & Alvotech Secure Approval for Europe’s First Ustekinumab Biosimilar to Stelara

STADA & Alvotech Secure Approval for Europe’s First Ustekinumab Biosimilar to Stelara

Partners STADA and Alvotech recently announced the European Commission issued a marketing authorization for Uzpruvo (AVT04), a biosimilar candidate to Stelara (ustekinumab). The centralized marketing….

Lexaria Bioscience Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug Delivery Platform

Lexaria Bioscience Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug Delivery Platform

Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWire (NNW), one of 60+ brands within the….

Enzene Biosciences Launches its First Manufacturing Base in the US, With Additional Plans to Establish Continuous Manufacturing Operations at its New Jersey Site

Enzene Biosciences Launches its First Manufacturing Base in the US, With Additional Plans to Establish Continuous Manufacturing Operations at its New Jersey Site

Widely recognized as a pioneer in continuous manufacturing, Pune-based Contract Development & Manufacturing Organization (CDMO), Enzene Biosciences has announced the launch of its first manufacturing site in the US, located in….

  WHITEPAPERS & WEBINARS

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..

WEBINAR - Enabling Upstream Intensified Bioprocessing

WEBINAR - Enabling Upstream Intensified Bioprocessing

Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Minimizing API Supply Chain Risks

WHITEPAPER - Minimizing API Supply Chain Risks

By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks

…

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 24 – Bioavailability
January 31 – Analytical Testing